Drug Trial Radar · NCT07399678
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Alveus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Conditions
- Overweight or Obese Adults
- Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100Drug
Participants will receive multiple ascending doses of ALV-100.
PlaceboDrug
Participants will receive placebo matching ALV-100, volume-matched to active dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: From First Dose to Week 52
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami
Miami, Florida
Ohio Clinical Trials
Columbus, Ohio
Endeavor Clinical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.